| Literature DB >> 25359993 |
Andre Weilemann1, Michael Grau2, Tabea Erdmann3, Olaf Merkel4, Ulduz Sobhiafshar5, Ioannis Anagnostopoulos6, Michael Hummel6, Antje Siegert7, Claudia Hayford8, Hannelore Madle3, Brigitte Wollert-Wulf9, Iduna Fichtner7, Bernd Dörken9, Stephan Dirnhofer10, Stephan Mathas9, Martin Janz9, N C Tolga Emre5, Andreas Rosenwald11, German Ott12, Peter Lenz2, Alexandar Tzankov10, Georg Lenz3.
Abstract
Anaplastic large cell lymphoma (ALCL) is a distinct entity of T-cell lymphoma that can be divided into 2 subtypes based on the presence of translocations involving the ALK gene (ALK(+) and ALK(-) ALCL). The interferon regulatory factor 4 (IRF4) is known to be highly expressed in both ALK(+) and ALK(-) ALCLs. However, the role of IRF4 in the pathogenesis of these lymphomas remains unclear. Here we show that ALCLs of both subtypes are addicted to IRF4 signaling, as knockdown of IRF4 by RNA interference was toxic to ALCL cell lines in vitro and in ALCL xenograft mouse models in vivo. Gene expression profiling after IRF4 knockdown demonstrated a significant downregulation of a variety of known MYC target genes. Furthermore, our analyses revealed that MYC is a primary target of IRF4, identifying a novel regulatory mechanism of MYC expression and its target gene network in ALCL. MYC, itself, is essential for ALCL survival, as both knockdown of MYC and pharmacologic inhibition of MYC signaling were toxic to ALCL cell lines. Collectively, our results demonstrate that ALCLs are dependent on IRF4 and MYC signaling and that MYC may represent a promising target for future therapies.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25359993 DOI: 10.1182/blood-2014-08-594507
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113